By The Associated Press
ROUGH QUARTER: Bristol-Myers Squibb Co. swings to a $711 million loss on a $1.8 billion charge for failed research and generic competition with decimated sales. It misses analysts' expectations and slashes its 2012 profit forecast.
THE NUMBERS: The loss equals 43 cents per share. Excluding charges Bristol made $969 million, or 56 cents per share. Generic competition to drugs including blood thinner Plavix, which had been the world's second-best-selling drug, cuts revenue 30 percent to $3.74 billion.
THE REACTION: One analyst says Bristol won't see much growth before 2020, and shares slide.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.